Search
pegaptanib ophthalmic (Macugen)
Tradename: Macugen (FDA-approved in 2004)
Indications:
- macular degeneration (exudative or wet form)
Dosage: intravitreous injection every 6 weeks [2]
Adverse effects:
1) anaphylaxis/anaphylactoid reactions
2) angioedema [2]
Mechanism of action:
- vascular endothelial growth-factor antagonist
Notes: Manufacturer: Eyetech/Pfizer
Related
macular degeneration
General
pegaptanib
ophthalmic agent (eyedrops)
References
- Prescriber's Letter 12(2): 2005
New Drugs Approved by the FDA in 2004
Detail-Document#: 210216
(subscription needed) http://www.prescribersletter.com
- FDA Medwatch
http://www.fda.gov/medwatch/safety/2006/safety06.htm#Macugen